Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN-101

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101). JEN-101 is a first-in-class, pre-clinical immuno-oncology agent based on Ankyra’s anchored platform. JEN-101 is composed of a fully canine interleukin-12 (IL-12) complexed with aluminum hydroxide. The drug is designed to be retained within tumors for an extended period and provide therapeutic